Avidity Biosciences Inc (NASDAQ:RNA) shares, rose in value, with the stock price up by 1.86% to the previous day’s close as strong demand from buyers drove the stock to $32.06.
Actively observing the price movement in the recent trading, the stock is buoying the session at $31.47, falling within a range of $30.995 and $32.31. The value of beta (5-year monthly) is 0.947. Referring to stock’s 52-week performance, its high was $56.00, and the low was $21.51. On the whole, RNA has fluctuated by -4.65% over the past month.
With the market capitalization of Avidity Biosciences Inc currently standing at about $3.86 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RNA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of RNA currently trading nearly 7.33% and 4.57% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.52, while the 7-day volatility ratio is showing 5.12% which for the 30-day chart, stands at 4.96%. Furthermore, Avidity Biosciences Inc (RNA)’s beta value is 0.93.
A comparison of Avidity Biosciences Inc (RNA) with its peers suggests the former has fared considerably weaker in the market. RNA showed an intraday change of 1.86% in today’s session so far, and over the past year, it grew by 10.23%%.
Data on historical trading for Avidity Biosciences Inc (NASDAQ:RNA) indicates that the trading volumes over the past 10 days have averaged 1.57 and over the past 3 months, they’ve averaged 1.43 million. According to company’s latest data on outstanding shares, there are 120.51 million shares outstanding.
Nearly 8.87% of Avidity Biosciences Inc’s shares belong to company insiders and institutional investors own 107.72% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.34 million shares as on 2025-06-13, resulting in a short ratio of 11.56. According to the data, the short interest in Avidity Biosciences Inc (RNA) stood at 1369.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 15.79 million. The stock has fallen by -20.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RNA stock heading into the next quarter.
